Fondaparinux for the Treatment of Heparin-Induced Thrombocytopenia (HIT)

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine how safe and effective fondaparinux is in treating patients with suspected or confirmed heparin-induced thrombocytopenia (HIT).

Clinical Trial Description

Currently, standard treatment of HIT involves the transition from a direct thrombin inhibitor (a type of anticoagulant or "blood thinner") to warfarin, a different type of anticoagulant. Direct thrombin inhibitors (DTIs) require IV administration and frequent blood draws for dose adjustments, which can lead to prolonged hospitalization. DTIs also affect blood test measurements, making it difficult to determine proper dosages of warfarin.

Fondaparinux is a drug that is approved by the FDA for the treatment of blood clots in deep veins and in the lungs. Fondaparinux is not FDA approved for the treatment of HIT. However, an increasing number of doctors are using fondaparinux instead of DTIs to treat HIT. Although fondaparinux appears to be more convenient and predictable than DTI medications, more research is needed to support its use as a treatment for HIT. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00673439
Study type	Interventional
Source	University of Louisville
Contact
Status	Terminated
Phase	Phase 2
Start date	November 2007
Completion date	September 2011

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT00759083` - Bivalirudin PCI Registry in Heparin Induced Thrombocytopenia/Heparin Induced Thrombocytopenia and Thrombosis Syndrome (HIT/HITTS) Patients	Phase 4
Completed	`NCT00412464` - Pilot Dose Finding and Pharmacokinetic Study of Fondaparinux in Children With Thrombosis	Phase 1
Completed	`NCT00456326` - Heparin-Induced Thrombocytopenia Registry	N/A
Active, not recruiting	`NCT00198575` - A Study on the Prevalence of Heparin-Induced Thrombocytopenia in Cardiovascular Patients	N/A
Completed	`NCT00283322` - Heparin Antibodies in Intensive Care Unit Patients (HAICU)	N/A
Not yet recruiting	`NCT05586854` - Multicenter Study on Dialysis Modalities for End-stage Chronic Renal Failure Patients With Heparin-induced Thrombocytopenia	N/A
Not yet recruiting	`NCT03269019` - Thrombotic Biomarkers to Predict Thrombosis in Heparin-induced Thrombocytopenia	N/A
Not yet recruiting	`NCT06066762` - Argatroban Monitoring in Acute Suspected Heparin-induced Thrombocytopenia.
Terminated	`NCT03809481` - Open-Label, Randomised, Active Controlled, Multi-Centre Phase 3 Study Safety and Efficacy of Danaparoid vs Argatroban	Phase 3
Completed	`NCT05325346` - A Phase I Study of the Co-administration of VLX-1005 and Argatroban in Healthy Human Subjects	Phase 1
Recruiting	`NCT02717039` - Pharmacogenomics of Heparin-Induced Thrombocytopenia
Completed	`NCT02526485` - Immunogenetics of Heparin-Induced Thrombocytopenia: Aim 2
Completed	`NCT00748839` - Heparin-Induced Thrombocytopenia: Development and Validation of a Predictive Clinical	N/A
Recruiting	`NCT05783895` - Comparison of Pre-test Probability Model for Heparin-induced Thrombocytopenia in Post-operative Cardiac Surgery
Not yet recruiting	`NCT04782843` - Evaluation of the Intra-observer Agreement of the HEP Score in Surgical Intensive Care.
Completed	`NCT00198588` - Efficacy and Safety Study of Argatroban to Treat Heparin-Induced Thrombocytopenia	Phase 3
Recruiting	`NCT04842760` - PLATELET Function Assay With Flow Imaging on ImageSTREAM Cytometer
Terminated	`NCT01598168` - Rivaroxaban for Treatment of Patients With Suspected or Confirmed Heparin-Induced Thrombocytopenia	Phase 3
Completed	`NCT01654848` - Heparin-induced Thrombocytopenia (HIT II) in Liver Transplant Recipients	N/A
Withdrawn	`NCT00603824` - Fondaparinux in Patients With Acute Heparin-Induced Thrombocytopenia (HIT)	Phase 4